Assembly Biosciences (ASMB) Common Equity (2010 - 2026)

Assembly Biosciences' Common Equity history runs 17 years deep, the most recent figure standing at $198.6 million for Q1 2026.

• In Q1 2026, Common Equity rose 631.99% year-over-year to $198.6 million; the TTM figure through Mar 2026 stood at $198.6 million (up 631.99% YoY), while the FY2025 annual figure was $206.8 million, up 519.78% from the prior year.
• Common Equity was $198.6 million for Q1 2026 at Assembly Biosciences, down from $206.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $206.8 million in Q4 2025 to a low of $18.1 million in Q2 2025.
• Historically, Common Equity has averaged $83.8 million across 5 years, with a median of $54.9 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Common Equity slumped 59.27% in 2023, then soared 631.99% in 2026.
• A 5-year view of Common Equity shows it stood at $82.7 million in 2022, then plunged by 50.28% to $41.1 million in 2023, then retreated by 18.83% to $33.4 million in 2024, then soared by 519.78% to $206.8 million in 2025, then decreased by 3.94% to $198.6 million in 2026.
• The last three Common Equity figures came in at $198.6 million (Q1 2026), $206.8 million (Q4 2025), and $182.7 million (Q3 2025), per Business Quant data.